natgillin/translations-raw huggingface dataset:
Do not use Saxenda if you are pregnant, think that you might be pregnant or are planning to have a baby. 
Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, zdravila Saxenda ne uporabljajte, saj ni znano, če vpliva na otroka.
The mean age was 64 years and the mean BMI was 32.5 kg/m². 
Povprečna starost je bila 64 let in povprečni ITM je bil
Early responders were defined as patients who achieved ≥5% weight loss after 12 weeks on treatment dose of liraglutide (4 weeks of dose escalation and 12 weeks on treatment dose). 
Izguba telesne mase po 12 tednih zdravljenja z liraglutidom (3,0 mg) Bolniki z zgodnjim odzivom so tisti, ki so po 12 tednih zdravljenja s terapevtskim odmerkom liraglutida (4 tedni povečevanja odmerka in 12 tednov na terapevtskem odmerku) dosegli ≥ 5 %
A majority of the reported events occurred in patients who had experienced nausea, vomiting or diarrhoea leading to volume depletion (see section 4.4). 
Večinoma se je pojavila pri bolnikih, ki so imeli zmanjšan volumen krvi (hipovolemijo) zaradi navzee, bruhanja ali driske (glejte poglavje 4.4).
Dose counter stopped: 
primer števec odmerka se je ustavil: preostalo je še
• Changed sense of taste 
• sprememba okušanja
Hypoglycaemia in patients with type 2 diabetes mellitus treated with insulin 
Hipoglikemija pri bolnikih s sladkorno boleznijo tipa 2, zdravljenih z insulinom
This is because it is not known if Saxenda passes into breast milk. 
Če dojite, zdravila Saxenda ne uporabljajte, saj ni znano, če prehaja v materino mleko.
In trial 4, more patients maintained the weight loss achieved prior to treatment initiation with liraglutide than with placebo (81.4% and 48.9%, respectively). 
V preskušanju 4 je več bolnikov (81,4 %), ki so prejemali liraglutid, obdržalo pred začetkom zdravljenja izgubljeno telesno maso, v primerjavi z bolniki, ki so prejemali placebo (48,9 %).
This may prevent blocked needles, contamination, infection, leakage of solution and inaccurate dosing. 
Tako lahko preprečite zamašitev igel, kontaminacijo, okužbo, puščanje raztopine in netočno odmerjanje.
In clinical trials in overweight or obese patients without type 2 diabetes mellitus treated with Saxenda in combination with diet and exercise, no severe hypoglycaemic events (requiring third party assistance) were reported. 
V kliničnih preskušanjih pri bolnikih s prekomerno telesno maso ali z debelostjo, ki niso imeli sladkorne bolezni tipa 2 in so bili zdravljeni z zdravilom Saxenda v kombinaciji z dieto in telesno vadbo, o hudih primerih hipoglikemije (ki bi zahtevala pomoč tretje osebe) niso poročali.
• Reduced kidney function 
• oslabljeno delovanje ledvic
No dose adjustment is required for patients with mild or moderate renal impairment (creatinine clearance ≥30 ml/min). 
Pri zdravljenju bolnikov z blago ali zmerno okvaro ledvic (očistek kreatinina ≥ 30 ml/min)
Hypoglycaemia in patients without type 2 diabetes mellitus 
Hipoglikemija pri bolnikih brez sladkorne bolezni tipa 2
At week 160, while on treatment, 3% treated with Saxenda and 11% treated with placebo were diagnosed with type 2 diabetes mellitus. 
V 160. tednu so med zdravljenjem sladkorno bolezen tipa 2 ugotovili pri 3 % bolnikov, ki so se zdravili z zdravilom Saxenda, in 11 % bolnikov, ki so prejemali placebo.
Among patients concomitantly treated with sulfonylurea, 60.9% of patients treated with liraglutide 3.0 mg/day and 60.0% of patients treated with placebo reported documented symptomatic hypoglycaemic events. 
Med bolniki, ki so hkrati prejemali sulfonilsečnine, so se simptomi hipoglikemije pojavili pri 60,9 % bolnikov, zdravljenih z liraglutidom 3,0 mg/dan, in pri 60,0 % bolnikov, ki so prejemali placebo.
Non-lethal thyroid C-cell tumours were seen in two-year carcinogenicity studies in rats and mice. 
V dveletni študiji kancerogenosti so pri podganah in miših opazili tumorje parafolikularnih celic ščitnice, ki niso bili smrtni.
Interaction studies have been performed with 1.8 mg liraglutide. 
Študije medsebojnega delovanja so izvedli z liraglutidom v odmerku 1,8 mg. Odmerka 1,8 mg in
The hazard ratio and 95% CI is 0.33 [0.12; 0.90] for liraglutide versus placebo. 
Razmerje ogroženosti in 95 % interval zaupanja za liraglutid v primerjavi s placebom je 0,33 [0,12; 0,90].
Cardiovascular evaluation 
Vrednotenje srčno-žilnega sistema
The effect on rate of gastric emptying was equivalent between liraglutide 1.8 mg and 3.0 mg, (paracetamol AUC0-300 min). 
3,0 mg imata enak učinek na hitrost praznjenja želodca (paracetamol AUC0-300 min).
You should see your doctor straight away if you get symptoms such as breathing problems, swelling of face and throat and a fast heartbeat. 
Nemudoma obiščite zdravnika, če se vam pojavijo simptomi, kot so težave z dihanjem,
What Saxenda is used for 
Za kaj uporabljamo zdravilo Saxenda
Stay on this programme while you are using Saxenda. 
Med uporabo zdravila Saxenda se držite predpisanega programa.
• Feeling generally unwell 
• splošno slabo počutje
Gastrointestinal disorders were the most frequently reported adverse events in two dose escalation studies completed so far. 
V dveh že zaključenih preskušanjih z višanjem odmerka so bili najpogosteje poročani neželeni učinki bolezni prebavil.
It is similar to a natural occurring hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. 
Podobno je naravnemu hormonu, ki ga imenujemo glukagonu podoben peptid 1 (GLP-1 - glucagon-like peptide
The use of Saxenda is not recommended if you have severe heart failure. 
Uporaba zdravila Saxenda ni priporočljiva za bolnike s hudim popuščanjem srca.
A Approx. how much solution is left 
A približna količina preostale raztopine
In the 160-week part of trial 1, the primary efficacy endpoint was the proportion of patients with onset of type 2 diabetes mellitus evaluated as time to onset. 
V 160-tedenskem delu preskušanja 1 so vrednotili čas do nastopa sladkorne bolezni tipa 2 pri
This may prevent blocked needles, contamination, infection and inaccurate dosing. 
S tem lahko preprečite zamašitev igel, kontaminacijo, okužbo in nenatančno odmerjanje.
If pancreatitis is suspected, liraglutide should be discontinued; if acute pancreatitis is confirmed, liraglutide should not be restarted. 
Če se akutni pankreatitis potrdi, se zdravljenja z liraglutidom ne sme več uvesti.
- if you are allergic to liraglutide or any of the other ingredients of this medicine (listed in section 6). 
Kaj morate vedeti, preden boste uporabili zdravilo Saxenda Ne uporabljajte zdravila Saxenda: - če ste alergični na liraglutid ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Injection site reactions have been reported in patients treated with Saxenda. 
Pri bolnikih, zdravljenih z zdravilom Saxenda, so poročali o reakcijah na mestu injiciranja.
1 ml solution for injection contains 6 mg liraglutide. 
1 ml raztopine za injiciranje vsebuje 6 mg liraglutida.
2 Check the flow • Before your first injection with each new pen, check the flow. 
• Pred injiciranjem zdravila z novim injekcijskim peresnikom vedno preverite pretok.
Hyperglycaemia in insulin treated patients with diabetes mellitus 
Hiperglikemija pri bolnikih s sladkorno boleznijo, ki se zdravijo z insulinom
Baseline values are means, changes from baseline at week 56 are estimated means (leastsquares) and treatment contrasts at week 56 are estimated treatment differences. 
Izhodiščni vrednosti telesne mase sta povprečji, spremembe v 56. tednu glede na izhodišče so ocenjena povprečja (metoda najmanjših kvadratov) in razlike v 56. tednu zaradi zdravljenja so ocenjene razlike zdravljenja.
Table 4 Trial 1: Changes from baseline in body weight, glycaemia and cardiometabolic parameters at week 160 
Preglednica 4 (preskušanje 1): Spremembe telesne mase, glikemije in srčno-presnovnih parametrov po 160 tednih glede na izhodišče
Mean change at week 32, % (95% CI) Mean change at week 32, kg (95% CI) 
Povprečna sprememba po 32 tednih v kg (95 % IZ)
Paracetamol (Acetaminophen) 
Paracetamol
Keep the cap on the pen in order to protect from light. 
Injekcijski peresnik naj bo pokrit s pokrovčkom za zagotovitev zaščite pred svetlobo.
Symptoms of hypoglycaemic events were reported by 1.6 % of patients treated with Saxenda and 1.1% of patients treated with placebo; however, these events were not confirmed by blood glucose measurements. 
Simptomi hipoglikemije so se pojavili pri 1,6 % bolnikov, zdravljenih z zdravilom Saxenda, in 1,1 % bolnikov, ki so prejemali placebo.
Saxenda (N=207) Placebo (N=206) Saxenda vs. placebo 
Preglednica 7 (preskušanje 4): Spremembe telesne mase po 56 tednih glede na izhodišče Saxenda (N=207) Placebo (N=206) Saxenda vs. placebo
• Press and hold down the dose button until the dose counter shows 0. 
• Pritisnite na potisni gumb in ga držite, dokler se na števcu odmerka ne pokaže 0.
Last observation carried forward. 
Prenos zadnjih opaženih vrednosti naprej.
(pancreatitis). 
• bruhanje.
and >10% weight loss with liraglutide than with placebo (tables 3-5). 
Večji delež bolnikov, vključenih v preskušanje, je doseglo ≥ 5 % in > 10 % izgubo telesne mase z liraglutidom kot s placebom (preglednice 3-5).
• Problems affecting the stomach and intestines, such as indigestion (dyspepsia), inflammation in the lining of the stomach (gastritis), stomach discomfort, upper stomach pain, heartburn, feeling bloated, wind (flatulence), belching and dry mouth 
• težave z želodcem in črevesjem, kot so: prebavne motnje (dispepsija), vnetje želodčne sluznice
Daily doses higher than 3.0 mg are not recommended. 
Ni priporočljivo uporabljati dnevnih odmerkov, ki so večji od 3,0 mg. Preglednica 1 Načrt povečevanja odmerka
Warfarin and other coumarin derivatives 
Varfarin in drugi kumarinski derivati Študija medsebojnega delovanja ni bila izvedena.
Full Analysis Set. 
Celotni nabor za analizo.
Contents of the pack and other information 
Shranjevanje zdravila Saxenda Vsebina pakiranja in dodatne informacije
Liraglutide exposure was reduced in patients with renal impairment compared to individuals with normal renal function in a single-dose trial (0.75 mg). 
Izpostavljenost liraglutidu v preskušanju z enkratnim odmerkom (0,75 mg) je bila pri bolnikih z okvaro ledvic manjša kot pri osebah z normalnim delovanjem ledvic.
Liraglutide did not change the overall exposure of atorvastatin following single dose administration of atorvastatin 40 mg. 
Liraglutid po enkratnem odmerku 40 mg atorvastatina ni spremenil celokupne izpostavljenosti atorvastatinu.
Sodium hydroxide (for pH adjustment) Water for injections 
klorovodikova kislina in natrijev hidroksid (za uravnavanje pH) ter voda za injekcije.
Each pen contains 3 ml solution and is able to deliver doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg. 
En injekcijski peresnik vsebuje 3 ml raztopine, z njim lahko injicirate 0,6 mg, 1,2 mg, 1,8 mg, 2,4 mg in 3,0 mg.
Table 6 Trial 3: Changes from baseline in body weight and Apnoea-Hypopnoea Index at week 
Preglednica 6 (preskušanje 3): Spremembe telesne mase in indeksa apneje-hipopneje po 32 tednih glede na izhodišče
Waist circumference, cm 
Obseg pasu v cm
Thyroid disease 
Srčne bolezni tahikardija
Talk to your doctor, pharmacist or nurse before using Saxenda. 
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila Saxenda se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Liraglutide lowered ethinylestradiol and levonorgestrel Cmax by 12% and 13%, respectively, following administration of a single dose of an oral contraceptive product. 
Liraglutid je po enkratnem odmerku peroralnega kontraceptiva zmanjšal Cmax etinilestradiola za 12 % in levonorgestrela za 13 %.
In a clinical trial in overweight or obese patients with type 2 diabetes mellitus treated with Saxenda in combination with diet and exercise, severe hypoglycaemia (requiring third party assistance) was reported by 0.7% of patients treated with Saxenda and only in patients concomitantly treated with sulfonylurea. 
V kliničnem preskušanju pri bolnikih s prekomerno telesno maso ali z debelostjo, ki so imeli sladkorno bolezen tipa 2 in so bili zdravljeni z zdravilom Saxenda v kombinaciji z dieto in telesno vadbo, je o hudi hipoglikemiji (ki je zahtevala pomoč tretje osebe) poročalo 0,7 % bolnikov.
Insomnia** 
Psihiatrične motnje nespečnost**
Name and address of the manufacturers of the biological active substance 
Ime in naslov proizvajalca biološke učinkovine Novo Nordisk A/S
Some patients may feel dizziness when taking Saxenda mainly during the first 3 months of treatment (see section ‘Possible side effects'). 
mesecih zdravljenja (glejte poglavje "Možni neželeni učinki").
Always make sure that a drop appears at the needle tip before you use a new pen for the first time. 
Preden prvič uporabite injekcijski peresnik, se vedno prepričajte, da se na konici igle pojavi kapljica.
For body weight, HbA1c, FPG, blood pressure and waist circumference, baseline values are means, changes from baseline at week 56 are estimated means (least-squares) and treatment contrasts at week 56 
Pri telesni masi, HbA1c, koncentraciji glukoze v plazmi na tešče in pri obsegu pasu so izhodiščne vrednosti povprečja, spremembe v 56. tednu glede na izhodišče so ocenjena povprečja (metoda najmanjših kvadratov) in razlike v 56. tednu zaradi zdravljenja so ocenjene razlike zdravljenja.
Acute renal failure Renal impairment 
Bolezni sečil akutna odpoved ledvic, okvara ledvic
Blood glucose self-monitoring is necessary to adjust the dose of insulin or insulin-secretagogues (see section 
Za prilagajanje odmerka insulina ali sekretagogov insulina je potreben bolnikov samonadzor glukoze v krvi (glejte poglavje 4.4).
• Before you use the pen for the first time, your doctor or nurse will show you how to use the pen. 
Kako in kdaj uporabljati zdravilo Saxenda • Preden prvič uporabite injekcijski peresnik, vam bo zdravnik ali medicinska sestra pokazal/-a,
The 56-week part of trial 1 assessed body weight loss in all the 3,731 randomised patients (2,590 completers). 
3.731 randomiziranih bolnikih (preskušanje je bilo zaključeno pri 2.590 bolnikih).
Among patients not concomitantly treated with sulfonylurea, 15.7% of patients treated with Saxenda and 7.6% of patients treated with placebo reported documented symptomatic hypoglycaemic events (defined as plasma glucose ≤3.9 mmol/L accompanied by symptoms). 
Med bolniki, ki niso hkrati prejemali sulfonilsečnine, so se simptomi hipoglikemije (določeni kot koncentracija glukoze v krvi ≤ 3,9 mmol/l ter spremljajoči simptomi) pojavili pri 15,7 % bolnikov, zdravljenih z zdravilom Saxenda, in pri 7,6 % bolnikov, ki so prejemali placebo.
Cases of inflammation of the pancreas (pancreatitis) have been reported uncommonly in patients using Saxenda. 
Pri bolnikih, zdravljenih z zdravilom Saxenda, so poročali o občasnih primerih vnetja trebušne slinavke (pankreatitisa).
Saxenda 6 mg/ml injection liraglutide 
Saxenda 6 mg/ml injekcija liraglutid za subkutano uporabo
Hypoglycaemia in patients with type 2 diabetes mellitus 
Hipoglikemija pri bolnikih s sladkorno boleznijo tipa 2
No dose adjustment is recommended for patients with mild or moderate hepatic impairment. 
Pri zdravljenju bolnikov z blago ali zmerno okvaro jeter prilagoditev odmerka ni potrebna.
Ethnic origin had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results of population pharmacokinetic analysis which included overweight and obese patients of White, Black, Asian and Hispanic/non-Hispanic groups. 
Glede na rezultate populacijske farmakokinetične analize, ki je zajela bolnike s prekomerno telesno težo in bolnike z debelostjo bele in črne rase ter bolnike iz azijskih in latinskoameriških skupin/nelatinskoameriških skupin, etnično poreklo ne vpliva klinično pomembno na farmakokinetiko liraglutida.
The average liraglutide steady state concentration (AUCτ/24) reached approximately 31 nmol/L in obese (BMI 30-40 kg/m2) patients following administration of 3 mg liraglutide. 
povprečna koncentracija liraglutida v stanju dinamičnega ravnovesja (AUCτ/24) dosegla približno 31 nmol/l.
After first use of the pen, store below 30°C or in a refrigerator Keep the pen cap on in order to protect from light 
Po prvi uporabi shranjujte injekcijski peresnik pri temperaturi do 30 °C ali v hladilniku.
Driving or use of machines should be exercised with caution if dizziness occurs. 
Če se pojavi omotica, je pri upravljanju vozil in strojev potrebna previdnost.
Hold the dose button down until the dose counter shows 0. 
Potisni gumb držite pritisnjen, dokler se na števcu odmerka ne pokaže 0.
Table 3 Trial 1: Changes from baseline in body weight, glycaemia and cardiometabolic parameters at week 56 
Preglednica 3 (preskušanje 1): Spremembe telesne mase, glikemije in srčno-presnovnih parametrov po 56 tednih glede na izhodišče
• Keep the needle in your skin after the dose counter has returned to 0 
• Ko se števec odmerka vrne na 0, iglo pustite v koži in počasi štejte do 6.
• Inflamed gall bladder 
• vnetje žolčnika
This may be due to feeling sick (nausea), being sick (vomiting) and diarrhoea. 
v primeru občutka slabosti (siljenja na bruhanje), bruhanja in driske.
Always use the dose counter and the dose pointer to see how many mg you have selected before injecting this medicine. 
Pred injiciranjem zdravila s števcem odmerka in kazalnikom odmerka vedno preverite, koliko mg ste izbrali.
1.8 mg once a day 
1,8 mg enkrat na dan teden 4
Once you start using the pen: 
Ko injekcijski peresnik začnete uporabljati
Signs and symptoms of dehydration, including renal impairment and acute renal failure, have been reported in patients treated with GLP-1 receptor agonists. 
Pri bolnikih, ki so se zdravili z agonisti receptorjev GLP-1, so bili opisani znaki in simptomi dehidracije, vključno z okvaro ledvic in akutno odpovedjo ledvic.
0.6 mg once a day 
0,6 mg enkrat na dan teden 2
The dose should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one week intervals to improve gastro-intestinal tolerability (see table 1). 
Končni odmerek 3,0 mg enkrat na dan je treba doseči postopoma, v korakih po 0,6 mg, da bi izboljšali prenašanje v prebavilih.
Increased lipase 
Preiskave povečana koncentracija lipaze,
In clinical trials, tachycardia was reported in 0.6% of patients treated with Saxenda and in 0.1% of patients treated with placebo. 
V kliničnih preskušanjih so o tahikardiji poročali pri 0,6 % bolnikov, zdravljenih z zdravilom
tmax was delayed by 1.5 h with liraglutide for both compounds. 
Pri sočasnem zdravljenju z liraglutidom se je tmax pri obeh učinkovinah podaljšal za 1,5 ure.
This is more likely to occur at the start of treatment and may be due to being sick (vomiting), feeling sick (nausea) and diarrhoea 
Občasni: pojavijo se lahko pri največ 1 od 100 bolnikov • izguba tekočine (dehidracija); bolj verjetno je, da se pojavi na začetku zdravljenja in je lahko posledica bruhanja, siljenja na bruhanje (slabost) in driske
The pen can dial up to a maximum of 3.0 mg. 
Z injekcijskim peresnikom lahko izberete največ 3,0 mg.
Digoxin median tmax was delayed from 1 h to 1.5 h. No dose adjustment of digoxin is required based on these results. 
Mediani tmax digoksina se je podaljšal z 1 na 1,5 ure.
Some severe allergic reactions (anaphylaxis) have been reported rarely in patients using Saxenda. 
Pri bolnikih, zdravljenih z zdravilom Saxenda, so poročali o redkih primerih hude alergijske reakcije (anafilaksija).
Liraglutide did not change the overall exposure of griseofulvin following administration of a single dose of griseofulvin 500 mg. Griseofulvin Cmax increased by 37% while median tmax did not change. 
Cmax griseofulvina se je povečala za 37 %, medtem ko se mediani tmax ni spremenil.
Exposure was significantly lower (44%) in patients with severe hepatic impairment (Child Pugh score >9). 
Izpostavljenost je bila bistveno nižja (44 %)
Proportion of patients losing >10% body weight at week 160, % (95% CI) 
Delež bolnikov, ki so izgubili > 10 % telesne mase do 160. tedna v % (95 % IZ)
Few cases of anaphylactic reactions with symptoms such as hypotension, palpitations, dyspnoea and oedema have been reported with marketed use of liraglutide. 
Po prihodu liraglutida na trg so v nekaj primerih poročali o anafilaktični reakciji, ki so jo spremljali simptomi, kot so hipotenzija, palpitacije, dispneja in edem.
Nausea Vomiting Diarrhoea Constipation 
Bolezni živčevja omotica, disgevzija
Only doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3.0 mg must be selected with the dose selector. 
1,8 mg, 2,4 mg ali 3,0 mg. Da zagotovite pravilen odmerek, mora biti izbrani odmerek natančno poravnan s kazalnikom odmerka.
Neonatal growth was reduced in rats while exposed to liraglutide and persisted in the post-weaning period in the high dose group. 
Pri podganah, ki so bile izpostavljene liraglutidu, se je upočasnila neonatalna rast, kar se je v skupini, ki je prejemala velik odmerek,
Stop taking Saxenda and contact a doctor immediately if you notice any of the following serious side effects: 
Če opazite katerega koli od naslednjih resnih neželenih učinkov, zdravilo Saxenda prenehajte uporabljati in se nemudoma posvetujte z zdravnikom:
Liraglutide did not change the overall exposure of paracetamol following a single dose of 1,000 mg. Paracetamol Cmax was decreased by 31% and median tmax was delayed up to 15 min. No dose adjustment for concomitant use of paracetamol is required. 
Največja koncentracija paracetamola (Cmax) se je zmanjšala za 31 %, mediani čas do največje koncentracije (tmax) pa se je podaljšal za največ 15 min.
When starting treatment with Saxenda, you may lose body fluid or become dehydrated. 
Izguba tekočine in dehidracija Po uvedbi zdravljenja z zdravilom Saxenda se lahko pojavi izguba telesne tekočine (dehidracija), npr.
Instructions on how to use Saxenda 6 mg/ml solution for injection in prefilled pen 
Navodila za uporabo zdravila Saxenda 6 mg/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Example 
Sprememba
Proportion of patients losing >10% body weight at week 56, % (95% CI) Full Analysis Set. 
telesne mase do 56. tedna v % (95 % IZ) Celotni nabor za analizo.
Treatment with liraglutide significantly reduced the severity of obstructive sleep apnoea as assessed by change from baseline in the AHI compared with placebo (table 6). 
ocenjene kot sprememba od izhodiščnega AHI v primerjavi s placebom (preglednica 6).
• Faster pulse. 
• zvišan srčni utrip
Figure 2 Cumulative distribution of weight change (%) after 56 weeks of treatment in trial 1 Table 5 Trial 2: Changes from baseline in body weight, glycaemia and cardiometabolic parameters at week 56 
Slika 2 Kumulativna porazdelitev spremembe telesne mase (%) po 56 tednih zdravljenja v preskušanju 1
Disodium phosphate dihydrate Propylene glycol 
- Druge sestavine zdravila so natrijev hidrogenfosfat dihidrat, propilenglikol, fenol,
Age had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results from a population pharmacokinetic analysis of data from overweight and obese patients (18 to 82 years). 
Glede na rezultate populacijske farmakokinetične analize podatkov bolnikov s prekomerno telesno maso in bolnikov z debelostjo (starih od 18 do 82 let) starost ne vpliva klinično pomembno na farmakokinetiko liraglutida.
Solution for injection 
Vzdrževanje injekcijskega peresnika
1.2 mg once a day 
1,2 mg enkrat na dan teden 3
1 pen 3 pens 5 pens 
1 injekcijski peresnik 3 injekcijski peresniki 5 injekcijskih peresnikov
Pancreatitis*** Delayed gastric emptying**** 
žolčnika in žolčevodov holelitiaza***
Proportion of patients losing ≥5% body weight at week 56, % (95% CI) 
≥ 5 % telesne mase do 56. tedna v % (95 % IZ)
Saxenda is not recommended for use in patients with severe renal impairment (creatinine clearance <30 ml/min) including patients with end-stage renal disease (see sections 4.4, 4.8 and 5.2). 
Zdravljenje z zdravilom Saxenda ni priporočljivo pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min), vključno z bolniki s končno odpovedjo ledvic
Proportion of patients losing ≥5% body weight at week 160, % (95% CI) 
Delež bolnikov, ki so izgubili ≥ 5 % telesne mase do 160. tedna v % (95 % IZ) 49,6